Artiva Biotherapeutics, Inc.(ARTV) - 2024 Q4 - Annual Results

Exhibit 99.1 Corporate and Financial Updates Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, cash equivalent ...